Author(s): Wilner AN
Abstract Share this page
Abstract Controversy persists whether generic antiepileptic drugs (AEDs) are interchangeable with brand name drugs with respect to efficacy and adverse events. Three hundred and one neurologists responded to a survey regarding generic AEDs mailed to 6420 neurologists, for an overall response rate of 4.7\%. One hundred and ninety-six (67.8\%) neurologists reported breakthrough seizures after a switch from a brand name to generic AED; 93 (32.2\%) did not. One hundred and sixty-three neurologists (56\%) reported increased side effects in their patients after a switch from a brand name to generic AED; 128 (44\%) did not. Fifty-two (18.4\%) neurologists agreed that the Food and Drug Administration standards for AED bioavailability are sufficiently narrow; 231 (81.6\%) did not.
This article was published in Epilepsy Behav
and referenced in